| 05/04/2026 4:58 PM | Emerald Bioventures, LLC (2020620) Reporting Galera Therapeutics (1563577) Issuer Opler Timothy (1706867) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 04/27/2026 3:14 PM | Emerald Bioventures, LLC (2020620) Filed by Galera Therapeutics (1563577) Subject | Form SCHEDULE 13D | |
| 04/22/2026 8:23 AM | Galera Therapeutics (1563577) Subject | Form 425 | |
| 04/22/2026 8:19 AM | Galera Therapeutics (1563577) Subject | Form 425 | |
| 04/20/2026 3:58 PM | Galera Therapeutics (1563577) Filer | Form DEF 14A | |
| 04/20/2026 4:01 PM | Galera Therapeutics (1563577) Filer | Form ARS | |
| 04/14/2026 4:13 PM | Galera Therapeutics (1563577) Subject | Form 425 | |
| 04/14/2026 4:15 PM | Galera Therapeutics (1563577) Subject | Form 425 | |
| 04/14/2026 4:18 PM | Galera Therapeutics (1563577) Subject | Form 425 | |
| 04/14/2026 8:18 AM | Galera Therapeutics (1563577) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/14/2026 8:23 AM | Galera Therapeutics (1563577) Subject | Form 425 | |
Get the Latest News and Ratings for GRTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 04/10/2026 11:29 AM | CHANG NANCY T (1135041) Filed by Galera Therapeutics (1563577) Subject | Form SCHEDULE 13D | |
| 04/09/2026 3:37 PM | CHANG NANCY T (1135041) Reporting Galera Therapeutics (1563577) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/09/2026 3:39 PM | FRIEDMAN MICHAEL R. (1993243) Reporting Galera Therapeutics (1563577) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/09/2026 3:01 PM | Galera Therapeutics (1563577) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/03/2026 5:03 AM | Galera Therapeutics (1563577) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/19/2026 6:15 AM | Galera Therapeutics (1563577) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/18/2026 5:01 AM | Galera Therapeutics (1563577) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/24/2025 3:42 PM | Galera Therapeutics (1563577) Issuer Sorensen Mel (1444783) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/20/2025 12:27 PM | Galera Therapeutics (1563577) Subject Sorensen Mel (1444783) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/13/2025 6:15 AM | Galera Therapeutics (1563577) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/27/2025 6:30 AM | Galera Therapeutics (1563577) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/21/2025 3:05 PM | Galera Therapeutics (1563577) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/13/2025 6:01 AM | Galera Therapeutics (1563577) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/15/2025 6:00 AM | Galera Therapeutics (1563577) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/05/2025 3:17 PM | Galera Therapeutics (1563577) Issuer Sorensen Mel (1444783) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/05/2025 3:19 PM | Galera Therapeutics (1563577) Issuer Sussman Joel F. (1774297) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |